Compare Alcon AG (ALC) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.29. The key difference: Alcon AG pays a 0.54% dividend while Direxion Daily FTSE China Bull 3x Shares pays none. Which is the better fit depends on your goals.
| ALC | YINN | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $92.22 | $56.62 |
52-Week Low | $62.02 | $21.45 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
YINN (Direxion Daily FTSE China Bull 3x ETF) trades at $23.30, up 5.53% with a bearish technical signal from moving averages. The ETF faces structural risks from its leveraged exposure to Chinese equities, though recent sentiment shows some improvement as China's tech sector benefits from AI investments and export growth. Key support sits at $22-23 with resistance at $24.
Outlook remains cautious due to YINN's leveraged structure and China's regulatory environment. While AI-driven growth and index rebalancing may provide short-term catalysts, long-term risks include geopolitical tensions and valuation concerns. Investors should weigh the ETF's daily reset mechanism against China's economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
